top of page
Pfizer RSV Vaccine
HCP
XXXXX
Sarah McKinnon (AD) | Kaio Mendes (AD) | Jake Silverman (AD) | Darian Momanaee (CW)
RSV is known as a pediatric illness but older adults are also at risk. We sought to change HCP's mindset and get everyone at risk for RSV vaccinated.
ACP Conference
This showing served as a statement piece that Pfizer was leading the charge for RSV vaccine development and to test our pre-campaign aesthetic, a ICU treating patients.
Epanels
Touch Screen Trivia Game
Keeping Omicron in mind, we developed a mobile version.
Booth: How it all came together.
Destination Beyond
The global Pfizer client team were all coming to NYC to discuss the future direction for their growing RSV brand. Our team set the stage for their thought-provoking meeting.
Welcome Poster
Message Platform
Disease Education: Hospital readministration is frequent, with nearly 1 in 5 older adults readmitted within 6 months
MoA: Only Product X features a dual vector and protein combination delivery system, resulting in a humoral and cellular immune response
Efficacy: Product X provides 2 years of 80% protection against more serious RSV symptoms, regardless of age or disease strain
Durability: The robust and durable immune response of Product X is sustained through 24 months
Immunogenicity: Less than 10% of patients experienced adverse effects that led to treatment discontinuation.
Safety: Adverse reactions were similar and mild regardless of risk factors, including age or comorbidities
Dosing: Product X is packaged in 2 single-dose, ready-to-mix liquid vials for intramuscular injection
Storage: Product X fits into your practice with no special refrigeration necessary
Campaign Concepting
In preparation for launch we put into testing our most compelling messages paired with campaign concepts for look and feel.
-2.png)
-3.png)
bottom of page